KRAS and non-small cell lung carcinoma: To date, sotorasib has been approved in over 45 countries.374 These promising data led to an ongoing Phase III study (CodeBreak 200; NCT04303780) to evaluate the efficacy of sotorasib vs. docetaxel as second-line therapy in advanced KRAS-G12Cmut NSCLC.